Ex-Trump official seeks to disrupt kidney care market with new startup

·2 min read

Adam Boehler was one of very few VC-backed founders who joined the Trump administration, leaving Landmark Health in 2018 to become director of the Center for Medicare and Medicaid Innovation. Now he's back in the private sector, with a new startup that wants to disrupt the kidney care market.

Why it matters: The CDC estimates that 15% of U.S. adults suffer from some form of chronic kidney disease, including more than 38% of those over 65 years old.

Get market news worthy of your time with Axios Markets. Subscribe for free.

  • There are plenty of businesses servicing this population, including a pair of publicly traded dialysis center giants. But Boehler argues they're too focused on fees, and too little on helping patients get at-home treatments or kidney transplants.

  • It's a case that's been made by several academic nephrology centers, with which Boehler says he wants to partner. It's also reminiscent of Landmark Health, which focused on at-home medical services and which was bought earlier this year by a UnitedHealth subsidiary for billions of dollars.

The new company is called Evergreen Health, and will be publicly unveiled later Tuesday.

  • It's under the umbrella of a healthcare incubator called Rubicon Founders, which Boehler recently formed with an undisclosed amount of funding from Oak HC/FT and Welsh, Carson, Anderson & Stowe. At least $25 million is being dedicated to Evergreen's launch.

Lessons learned: Boehler says his big takeaway from Landmark Health was that physicians will change their behavior if compensation is linked more to patient outcomes than to their procedures.

  • "We told physicians that we were going to pay them very well, but pay them very well for treating patients the way they wanted to when they went to medical school ... Who gives a shit how many patients you can see in a day at a dialysis center? Instead of seeing 20 patients, see three and get them to a place where they can be treated at home or get a transplant."

  • Boehler, who also served as the first-ever CEO of the U.S. International Development Finance Corp., adds that his big lesson from government was that it has a lot more smart and talented people than he realized while in the private market, and says "there's no platform like it in terms of making an impact if you're willing to lean in."

Look ahead: Expect Rubicon Founders to continue launching new companies focused on health markets that it considers to have at least $1 billion of value opportunity.

More from Axios: Sign up to get the latest market trends with Axios Markets. Subscribe for free

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting